MedDRA preferred term · the medicine was given by the wrong route

Incorrect route of drug administration: adverse event reports recording this term

35,775 reports to FDA record it, 2005–2018; 0.2% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

35,775
reports recording the term: 0.2% of all reports; 0
reports, 12 months to June 2026: 0 in the 12 months before; 20%
marked serious by the reporter: 57.4% across all reports; 3%
record death among outcomes, as reported: 9.1% across all reports

"Incorrect route of drug administration" (in plain words, the medicine was given by the wrong route) is a MedDRA preferred term recorded in 35,775 adverse event reports received by FDA, 0.2% of the database, from April 2005 to September 2018. The term is chosen by whoever codes the report to match what the reporter described.

0 reports recorded it in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 20% are marked serious, 3% include death among the outcomes and 7.9% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Tiotropium bromide, Humira and Cosentyx. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Tiotropium bromide	Anticholinergic	23,266	30.2%
Humira	—	620	0.1%
Cosentyx	Interleukin-17A antagonist	406	0.3%
Enbrel	Tumor necrosis factor blocker	381	0.1%
Prolia	RANK ligand inhibitor	331	0.2%
Saphris	Atypical antipsychotic	200	3.1%
Fentanyl	Opioid agonist	189	0.4%
Duodopa	—	163	0.9%
Opana Er	—	133	0.4%
Nexplanon	Progestin	127	0.3%
Avonex	Interferon beta	120	0.1%
Fentanyl citrate	Opioid agonist	111	0.7%
Subutex	—	105	1.8%
Humira 40 Mg/0 8 Ml Pen	—	104	0.7%
Repatha	PCSK9 inhibitor	103	0.1%
Mupirocin	—	101	3.4%
Xgeva	RANK ligand inhibitor	96	0.4%
Risperdal Consta	—	91	0.7%
Stelara	Interleukin-12 antagonist	84	0.1%
Fentanyl Transdermal System	—	83	0.7%
Baclofen	gamma-Aminobutyric acid-ergic agonist	82	0.4%
Imitrex	Serotonin-1b and Serotonin-1d receptor agonist	82	1.1%
Doxorubicin hydrochloride	Anthracycline topoisomerase inhibitor	79	0.2%
Implanon	—	79	0.8%
Xolair	Anti-IgE	79	0.1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.2% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Anticholinergic	23,299	14.6%	0%
Opioid agonist	623	0.1%	0%
Atypical antipsychotic	454	0.1%	0%
Tumor necrosis factor blocker	437	0%	0%
RANK ligand inhibitor	427	0.3%	0.2%
Interleukin-17A antagonist	410	0.2%	0%
Corticosteroid	376	0%	0%
Benzodiazepine	243	0.1%	0.1%
Progestin	188	0.1%	0%
Amide local anesthetic	171	0.4%	0.3%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.4%157

2 to 110.8%283

12 to 170.7%253

18 to 446.6%2,352

45 to 6414.9%5,342

65 to 7413.4%4,785

75 and over12.1%4,333

Age not given51.1%18,270

Patient sex

Female55.7%19,922

Male34.5%12,329

Not given9.9%3,524

Grey bar: all 20,646,523 reports in the database. 79.2% of these reports give the United States as the country.

Questions about "Incorrect route of drug administration"

What does "Incorrect route of drug administration" mean in an adverse event report?

In plain language: the medicine was given by the wrong route. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record incorrect route of drug administration?

35,775 reports through June 2026 (0.2% of all reports), 0 of them in the latest 12 months.

Which drugs appear most often in these reports?

Tiotropium bromide (23,266), Humira (620), Cosentyx (406), Enbrel (381) and Prolia (331). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.